Vedang Murthy presented results of the phase III BART trial at ASTRO24

Dr. Vedang Murthy, MD, is a Professor and Radiation Oncologist at Tata Memorial Hospital, Mumbai, specializing in urological cancers. He is an expert in advanced radiotherapy techniques, including IGRT and SBRT, with a focus on high-risk prostate cancer, kidney cancer, oligometastatic prostate cancer, and bladder preservation.

Murthy presented the results of the multicentric phase III bladder adjuvant RT (BART) trial at ASTRO24.

“Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicentre Randomized Controlled Trial: Acute and late toxicity in BART RCT”

Authors: Vedang Murthy, Priyamvada Maitre, Ganesh Bakshi, Mahendra Pal, Maneesh Singh, Rakesh Sharma, Duleep Gudipudi, Lincoln Pujari, Himanshu Pandey, Bhavesh Bandekar, Deepa Joseph, Rahul Krishnatry, Reena Phurailatpam, Sadhana Kannan, Amandeep Arora, Ankit Misra, Amit Joshi, Vanita Noronha, Kumar Prabhash, Santosh Menon, and Gagan Prakash.

On this occasion, healthcare professionals and organizations shared on social media:

TMC Radiation Oncology:

“Dr. Murthy stole the show at ASTRO2024 while raising the BAR(T)!

Vedang Murthy presenting results of the multicentric phase III bladder adjuvant RT (BART) trial ASTRO2024 with a punch of brilliance and flair!

And what’s more, with a simultaneous publication in IJROBP!”

Justin Barnes:

“Tata Memorial Hospital continues to raise BART with another critical and practical study.

Vedang Murthy, TMC Radiation Oncology, Postop RT (bed + nodes) vs observation for high risk MIBC.

• Low acute toxicity.
• 10% (vs 8%) G3+ late toxicity
• 15% (vs 7%) G2 late toxicity.”

Ananya Choudhury:

“Worried about toxicity with adjuvant RT post-cystectomy?

Vedang Murthy presents BART trial toxicity results. There is no significant difference. These are high risk patients, 70% had NAC. Paper in IJROBP.

Take home to surgeons/radoncs – Don’t worry!”

IJROBP – The Red Journal:

“We are honored to publish rapid online Dr. Vedang Murthy’s BART trial simultaneous with its presentation at Clinical Trials session today. Ballroom A/B/C now.

Editorial by Brian Baumann, Jason Efstathiou.

BART.

Editorial.”

UroToday:

“Bladder adjuvant radiotherapy (BART): acute and late toxicity from a phase III multicenter randomized controlled trial. Presentation by Vedang Murthy, Tata Memorial Hospital. ASTRO24 written coverage by Rashid Sayyid, USC on UroToday.”

Ben Slotman:

“Great talk by Vedang Murthy on bladder adjacent radiotherapy at ASTRO24 showing low toxicity rates. Conclusion: No need to be afraid!”

Nat Lester-Coll:

“ASTRO24 Clinical Trials

Vedang Murthy presents BART – largest RCT of adjuvant RT in bladder cancer.

Severe acute and late toxicity were low and similar between the two arms.

Ontological outcomes are awaited.”

Colton Ladbury:

“Vedang Murthy from TMC Radiation Oncology shows that adjuvant RT for high risk bladder cancer post-cystectomy is well tolerated. LRFS results eagerly awaited.”

Shankar Siva:

“Vedang Murthy continues to raise the Bar(t) with randomised trials in GU Cast, radiotherapy trials. Adjuvant RT in high risk bladder cancer; 8-year accrual, with good safety signal (acute and late tox). Majority of patients had chemotherapy, pN+ve or T3+.”

More posts featuring ASTRO24 on oncodaily.com